John Dwyer

President, Global Alzheimer’s Platform Foundation; Founding Board Member, UsAgainstAlzheimer's

John Dwyer is the President of the Global Alzheimer’s Platform (GAP) Foundation.The GAP Foundation is dedicated to making the clinical trial process for Alzheimer’s therapies substantially more efficient thereby speeding cures to patients afflicted with this insidious disease. Mr. Dwyer is a serial healthcare entrepreneur who most recently participated in the acquisition of MeYou Health, upon whose Board he now serves. Prior to GAP, he served as the co-founder and Chairman of Telcare, Inc., a high technology manufacturer of the first wirelessly enabled blood glucose meter designed to empower patients with diabetes to better manage their disease.

Mr. Dwyer first became a CEO at the age of 30. In the following years, he has held “C” level positions in six emerging growth companies in the healthcare industry. His past assignments have included serving as CEO of e-Medex, Inc., which later merged with Active Health Management to become the leading provider of population health management services, where he served as the Chief Operating Officer. Active Health was purchased by Aetna in 2005. He was also a co-founder and Chairman of CodeRyte, Inc., a venture-backed seller of medical billing software using natural language processing to generate billing codes. CodeRyte was purchased by 3M in 2012.

In addition to co-founding UsAgainstAlzheimer’s, he co-founded the first political action committee focused on a specific disease, the Alzheimer’s Action PAC. He began his career as an attorney with the Washington, D.C., based law firm of Arent, Fox LLP, where he focused on transactions in regulated industries.

He currently serves on the Boards of Directors of a number of private and not-for-profit organizations. Mr. Dwyer is a graduate of Marquette University and the Cornell Law School.

Read more

This Speaker's Sessions

Town Hall
Wednesday Oct. 12
-
3:30–4:15 PM
Watch Replay
Now Live!

Beyond Contemplating the Challenge of Inclusion in Clinical Trials

Clinical trials have traditionally fallen short when it comes to including people who are truly representative of the Alzheimer’s population. Recently successful efforts, however, are dispelling myths about the inclusion challenge. For example, among the 389 participants in the Evaluating Minority Patients with Actemra (EMPACTA) study approximately 84% were from Black, Hispanic, Native American, and other historically underrepresented groups. Key Question: What strategies successfully recruit, enroll, and retain participants who represent all of Us, especially those disproportionately affected?

View SessionWatch Replay